SOLICITATION NOTICE
66 -- Beckman coulter Vi-Cell XR
- Notice Date
- 9/10/2010
- Notice Type
- Presolicitation
- NAICS
- 334516
— Analytical Laboratory Instrument Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-100241-CR
- Archive Date
- 10/2/2010
- Point of Contact
- Caren N Rasmussen, Phone: (301) 402-4509
- E-Mail Address
-
cr214i@nih.gov
(cr214i@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- The National Cancer Institute (NCI), Center for Cancer Research (CCR), Experimental Transplantation and Immunology Branch (ETIB) plans to procure on a sole source basis the brand name Vi-Cell XR from Beckman Coulter, Inc., 4300 N. Harbor Blvd., Fullerton, CA 92835. This acquisition will be processed under the procedures for FAR Part 12 - Acquisition for Commercial Items and will be made pursuant to the authority in FAR 13.106-1(b)(2) and 13.501-(a)(1) using simplified acquisition procedures for commercial acquisitions. The North American Industry Classification System code is 334516 and the business size standard is 500 employees. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. Delivery Date: Two months after award. The Antibody Technology Section within the Experimental Transplantation and Immunology Branch pursues a concerted drug and target discovery approach with the objectives (i) to discover new antigens on the surface of leukemia cells that allow highly selective recognition and destruction, (ii) to generate and evolve monoclonal antibodies to these antigens, and (iii) to engineer innovative monoclonal antibody constructs that enhance leukemia cell destruction. The defined mission of the Antibody Technology Section (ATS) requires specialized equipment. At the core of research in the area of antibody technology are cytotoxicity assays that rely on the precise counting of both viable leukemia cells ("target cells") and viable immune cells ("effector cells") the antibody molecule recruits for killing leukemia cells. The ATS employs both cell lines and primary cells as target and effector cells; the ATS currently relies on manual cell counting which is time consuming and less accurate compared to automated cell counting. The purpose of this requirement is to equip the ATS with an automated cell counter to facilitate high throughput experiments with multi parameter evaluation. Primary cells (typically peripheral blood mononuclear cells from healthy volunteers and leukemia patients) are too small for reliable counting with most instruments, in particular for viability analysis. An instrument that meets these needs is the Beckman Coulter Vi-Cell XR. The following salient characteristics apply to the Beckman Coulter Vi-Cell XR:  Automates the Trypan Blue Dye Exclusion Method  Viability Range: 0-100%  Concentration Range: 5 x 104 to 1 x 107 cells/mL  Range: 2 um - 70 um  Minimum Sample Volume: 0.5 mls  Analysis Time: 2.5 minutes  Auto Focus Camera  1394 x 1040 CCD array  Firewire Camera  Image Zoom Capability  Bioprocess Tracking for Multiple Runs  Filled Cup Dispense Tray Flagging  Out of Range Concentration Flagging  Circularity Measurement  User defined Declustering Measurement  Non-Viable Cell Declustering Measurement  Operator Selectable Aspiration and Staining Mixing Cycles  Export Multi-run files to Microsoft Excel Software  21 CRF Part 11 Enabled  Self Contained, Validated Reagent Package Beckman Counter is the sole manufacturer of the Vi-Cell XR and is the only source that can provide this specialized equipment. It is the only instrument on the market that meets the automated cell counting needs of the Antibody Technology Section which, in addition to the salient characteristics of the equipment as outlined above, will allow the export of multi-run files to Microsoft Excel software. This is not a solicitation for competitive quotations. However, if any interested party believes they can meet the above requirement, they may submit a statement of capabilities. All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statement must be received at the NCI Office of Acquisitions on or before 11:00 AM EST on September 17, 2010. No electronic capability statements will be accepted (i.e. email or fax); an original and one copy must be sent to the NCI Office of Acquisitions to the address stated above. All questions must be in writing and can be faxed (301) 402-4513 or emailed to Caren Rasmussen, Contracting Officer at rasmussca@mail.nih.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) www.ccr.gov and the Online Representations and Certifications Applications (ORCA), http://orca.bpn.gov. No collect calls will be accepted. Please reference solicitation number NCI-100241 on all correspondences.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-100241-CR/listing.html)
- Record
- SN02276920-W 20100912/100911000257-ebee34ca60cbe1afc76afdcbb836f374 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |